ArticleDiscover oncology2026
Male accessory breast mucinous carcinoma: a case report and literature review.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accessory breast carcinoma represents a distinct ectopic malignancy comprising approximately 0.3-0.6% of all mammary neoplasms, of which male accessory breast cancer is even rarer. This condition typically manifests as a progressively enlarging mass, predominantly situated in the axillary or inguinal regions, and may present with early lymph node metastasis. Pathological examination remains the diagnostic gold standard, whereas ultrasound, mammography, and MRI serve as critical adjunctive modalities. Current therapeutic strategies for accessory breast carcinoma largely mirror established breast cancer protocols, establishing surgical resection as the cornerstone, followed by adjuvant endocrine therapy, chemotherapy, and radiotherapy. Here, we report a case of a 72-year-old male with accessory breast cancer. The patient was diagnosed with right axillary accessory breast cancer with right axillary lymph node metastatic cancer in 2021 and underwent right accessory mastectomy plus right axillary lymph node dissection at our hospital. Postoperatively, the patient completed adjuvant chemotherapy and remains on maintenance endocrine therapy. In 2025, a follow-up examination revealed a new mass in the medial aspect of the right upper arm near the axilla. Histopathological evaluation of the excised specimen confirmed features consistent with mucinous breast carcinoma. This report seeks to heighten clinical vigilance regarding male accessory breast carcinoma by providing a comprehensive delineation of its diagnostic trajectory, clinical progression, and therapeutic management in an exceptionally rare presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.